This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Mouse Malondialdehyde (MDA) ELISA Kit-Competitive
Product Overview
BioVenic Mouse Malondialdehyde (MDA) ELISA Kit-Competitive is designed for the quantitative determination of Mouse MDA in serum, plasma, tissue homogenate, cell culture supernatant, cell lysate, and other biological fluids using a Competitive ELISA method. For research use only.
Specifications
Target Information
In mice, malondialdehyde (MDA) serves as a key indicator of lipid peroxidation and is commonly used to evaluate oxidative stress levels and the extent of cellular damage. The production of MDA is closely linked to the generation of free radicals, particularly reactive oxygen species (ROS) that are formed during lipid peroxidation. As a byproduct of this process, MDA is often employed to gauge oxidative stress levels in the body. For instance, the TBA (thiobarbituric acid) reaction for measuring MDA content can indicate the level of lipid peroxidation, thereby assessing the degree of oxidative stress-induced damage to cells and tissues. Moreover, elevated MDA levels are associated with cell membrane damage, mitochondrial dysfunction, and apoptosis. MDA is of significant biological importance in various pathological conditions. For example, in models of acute pancreatitis, heightened MDA levels suggest that oxidative stress significantly contributes to the disease's development. Additionally, MDA can form cross-links with proteins and nucleic acids, leading to alterations in cell structure and function, which exacerbate cellular damage.
Shipping and Storage
This product is shipped with gel ice packs. It is recommended to store at 2-8 °C (Up to 6 months).
Documents
The product is for research use only.
Not for commercial, prophylactic, diagnostic, or therapeutic applications.
References
- Siriviriyakul, Prasong et al. "Genistein attenuated oxidative stress, inflammation, and apoptosis in L-arginine induced acute pancreatitis in mice." BMC complementary medicine and therapies vol. 22,1 208. 4 Aug. 2022.